Erlanger Hospital Opens CIDP Clinical Trial
The Chattanooga medical center is now enrolling adult patients in a late-stage study for a rare neurological condition.
Updated on Oct. 21, 2026 in Alzheimer’s
Live Poll
Would you consider participating in a clinical trial to gain access to an investigational medical treatment?
Erlanger Hospital in Chattanooga has begun enrollment for phase three clinical trials targeting chronic inflammatory demyelinating polyneuropathy (CIDP). The study seeks to evaluate the safety and efficacy of an investigational drug for adults living with the condition.
Why it matters
Clinical research serves as a critical pathway to expanding treatment options for rare diseases, which currently lack sufficient FDA-approved therapies. This trial provides a local opportunity for patients to potentially access new care protocols for their condition.
Approximately 30 million Americans live with a rare disease, yet fewer than 5% of these conditions have an FDA-approved treatment. This phase three study is currently evaluating both the safety and the functional efficacy of the investigational drug.
The players
Erlanger Hospital
This hospital serves as a leading academic medical center and the primary site for clinical research trials in the Chattanooga area.
The details
The trial is designed to assess how the experimental medication functions within the bodies of adults diagnosed with CIDP. Participants will contribute to findings on a condition characterized by progressive weakness and sensory loss, providing essential research data.
Timeline
Enrollment for the phase three clinical trial is active as of October 2026.
The Big Picture
The study at Erlanger Hospital follows a pattern set by the Orphan Drug Act of 1983 to incentivize medical development for rare conditions. This research aligns with efforts to bridge the gap between the prevalence of rare diseases and the availability of treatments.
Eligible adults in Chattanooga living with CIDP may now participate in this clinical trial, offering potential access to an experimental treatment. Prospective participants should consult with their healthcare providers to determine if they meet the specific enrollment criteria.
The takeaway
Advancements in rare disease research depend heavily on clinical trial participation to demonstrate safety and effectiveness. Residents should discuss the potential risks and benefits of experimental therapies with their medical teams.
Further reading
For more information on ongoing medical studies in the region, visit the Chattanooga Alzheimer’s section.
More information
For details on eligibility and study participation, visit the clinical trial enrollment and information.
Source note: This article includes information reported by News 12 Now.
Live Poll
Would you consider participating in a clinical trial to gain access to an investigational medical treatment?
